Zydus Wellness Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/wzc505bkedc0r6415v51b6xs.pdf

Key Takeaways


The Glucon-D Shock

Tarun Arora: "we do not have a doubt in terms of the fact that we can deliver a consistent over three years to four years, double-digit growth."

Complan & the HFD Price War

Dr. Sharvil Patel: "I think also this whole -- the lower price point architecture that got introduced, I think, has a detrimental effect on the overall category. So maybe short term, it looked very good, but it has destroyed the whole pricing architecture."

Sugar Free: A Category at a Crossroads


Margin Structure & Cost Headwinds

Tarun Arora: "we believe that in the next two years to three years, we should be looking at recovering back to 17% to 18% because we dropped down to 15%... we have to invest back also."

Competitive Dynamics & Disclosure Boundaries

Dr. Sharvil Patel: "I don't think you can combine two brands and say, become number one like that because each brand has its own capability and own customer set. So you don't replace just because -- you don't combine brands like that."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthStill has a shot at double-digit for the full year, with three quarters remaining including a large Q4FY24 (hopeful, not assured)
EBITDA margin recoveryClimb back to 17–18% from current ~15%Next 2–3 years
Working capital improvement10–13 days improvement vs. last yearFY24
Volume-led growthConsistent double-digit volume growth, accelerated by innovationsOver 3–4 years
Milk price pass-throughAppropriate price increases to address milk inflationComing quarters
Marketing investment focusSugar Free and Everyuth receive focused spend; others measuredNext six months

Key Metrics

MetricQ1 FY24
Net sales₹699.2 cr, +0.9% YoY
Total income from operations₹702.1 cr, +0.8% YoY
EBITDA₹116.5 cr, -21.3% YoY
EBITDA margin16.7% (per an analyst's math)
Reported net profit₹110.4 cr, -19.4% YoY
Adjusted net profit (excl. exceptional items)₹124.6 cr, -10.9% YoY
One-time expenditure₹14.2 cr, towards worker settlement, legal charges and inventory write-offs
Other expenses growth+13.6% YoY, driven by alternative fuel costs and statutory wage increases
Overall volume growth-5.2% YoY
Volume growth excl. Glucon-D+4.5% YoY
Non-milk portfolio gross margin improvement>100 bps YoY
EBITDA margin target (medium-term)17% to 18% over next 2-3 years, recovering from 15%
Glucon-D market share59.9%, -57 bps YoY (MAT June '23)
Complan market share4.5% (MAT June '23)
Complan household usage growth+12% at MAT level
Sugar Free market share96.2%
Everyuth scrub market share42.4%, +42 bps YoY (MAT June '23)
Everyuth peel-off market share78.7%, +19 bps YoY (MAT June '23)
Nycil market share35.5%, +117 bps YoY (MAT June '23)
Working capital improvement target10 to 13 days improvement vs last year
Tax benefit availabilityUntil March '25, normal tax rate applicable